MRI and lung function measures of benralizumab response in asthma
Research type
Research Study
Full title
Using benralizumab to explore treatment response patterns in functional lung MRI and advanced measures of lung function.
IRAS ID
274188
Contact name
Ian Sabroe
Contact email
Sponsor organisation
Sheffield Teaching Hospitals NHS Foundation Trust
Duration of Study in the UK
2 years, 6 months, 1 days
Research summary
New treatments have been developed for asthma that are good at preventing asthma attacks and improving day-to-day symptoms. Alongside the development of these new drugs, we have new ways of measuring how the lung is affected by asthma. In particular, we have developed ways of seeing how air moves in the lungs of people with asthma, using MRI scanning. This study aims to see how quickly these new drugs result in changes in the way the lung is working, as seen in the MRI scans and other breathing tests. This will help us in the future to decide who is likely to respond to these new medicines, and once we have started the drugs, will help us to decide whether long term treatment is likely to benefit the people receiving them.
In this study, we plan to do extra breathing tests and MRI scans on people who are receiving the drug as part of their usual clinical care. The study will not change an individual’s treatment, but will give us more information about their illness and the way their body responds to treatment.
REC name
Yorkshire & The Humber - Sheffield Research Ethics Committee
REC reference
20/YH/0003
Date of REC Opinion
2 Apr 2020
REC opinion
Further Information Favourable Opinion